Drug · DIN 02262835
STRATTERA
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since May 29, 2023; first marketed March 3, 2005.
- Drug Identification Number (DIN)
- 02262835
- Company (DIN owner)
- Eli Lilly Canada IncToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Atomoxetine N06BA09
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) | 40 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 24, 2004: NOC 6018New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “strattera”. A notice may cover another product or only some lots: read it to see what it covers.
- STRATTERA (atomoxetine) – Association with Increased Blood Pressure and Increased Heart Rate – For the PublicOctober 24, 2011 · Drugs
- Strattera (atomoxetine) - Association with Increased Blood Pressure and Increased Heart Rate - For Health ProfessionalsOctober 24, 2011 · Drugs
- Important Safety Information on Strattera (atomoxetine hydrochloride) and the potential for behavioral and emotional changes, including risk of self-harm- For Health Professionals- Eli Lilly Canada Inc.September 28, 2005 · Drugs
Other DINs named STRATTERA
- DIN 02262800 · Cancelled Post Market
- DIN 02262819 · Cancelled Post Market
- DIN 02262827 · Cancelled Post Market
- DIN 02262843 · Cancelled Post Market
- DIN 02279347 · Cancelled Post Market
- DIN 02279355 · Cancelled Post Market